EULAR 2023 – Day 3 Report https://t.co/qseMZiaHFq https://t.co/pnijisF9Jt

• https://bit.ly/3qpjtQF

Unmasking Lupus Pregnancy: Adherence and Drug Monitoring Dilemmas Preliminary data from a lupus pregnancy LEGACY cohort presented at #EULAR23 are alarming. Dr. Bella Mehta ( @bella_mehta ) shares more. https://t.co/cY2G4s4yR0 https://t.co/isepEb8OXD

• https://bit.ly/3CcgPQV

RA and cancer risk in the biologic era RA is known to be historically associated with site specific cancers, especially lung skin and lymphomas. This risk was described as likely to be supported by chronic systemic inflammation before the biologic era. https://t.co/4Pe6SIS6yb https://t.co/e2enjkXoly

• https://bit.ly/3qpKfsd

AI in RA: the story grows along the patient pathway The use of AI to analyse large data sets using its subset component machine learning (ML) has taken centre stage recently in the management of rheumatic conditions including RA. https://t.co/Jv4dmV2tlU https://t.co/KkgW0cD1QM

• https://bit.ly/42g6pKt

#EULAR23 – Day 2 Report Day 2 at the international EULAR Congress meeting is always bigger and busier. There are more sessions to choose from and more audience questions in the big auditorium presentations. https://t.co/vjrG7ez2fX https://t.co/HUuDImzqZA

• https://bit.ly/3oK70GI

EULAR points to consider in the match from PSO to PSA. 5 overarching principles and 10 points to consider. The presence of synovitis in PSO could be used as an outcome for prevention trials, Zabotti A et al, Abst#OP0062 #EULAR2023 @RheumNow https://t.co/tbnuhBCjTU

The definition of early axSpA based on expert consensus after going through the Delphi process by ASAS is that the duration of axial symptoms is equal or less than 2 years. Navarro-Compan V, Abst#OP0055 #EULAR2023 @RheumNow https://t.co/5byn0kBEIQ

Dual IL-17A/F inhibition with Bimekizumab reduced MRI inflammatory change in the SIJ and spine in AxSpA, and increasing proportion achieving MRI remission at Wk52, Abst#POS0246 #EULAR2023 @RheumNow https://t.co/w4VkkUklGl

The International Map of AxSpA (IMAS) of >5k patients: delay mean 7.4+/-9 years, 75% active disease, 60% poor mental health, 21% sick leave, 4.6 GP visits before diagnosis, fear=disease progression, hope=relief of pain, IMAS Abst#POS0298 #EULAR2023 @RheumNow https://t.co/wB9Jtbgvy7

Important from @cappelliMD @jhrheumatology irAE cohort on predictors of DMARD requirement in ICI-inflammatory arthritis, and persistent ICI-IA post-ICI cessation. The better we can predict these patients, the more we can get the right therapy early POS0951 #EULAR2023 @RheumNow https://t.co/YGTRl71505

EULAR 2023 recommendations on the management of fatigue in IRMDs. 4 overarching principles and 4 recommendations for monitoring and assessment of fatigue, Dures E Abst#P0370 #EULAR2023 @RheumNow https://t.co/AirPlRLNjZ

The course of symptoms in CSA to RA showed greater severity in the ACPA+ group compared to the ACPA- group. This correlated with MRI-subclinical joint score, suggesting different underlying processes Khidir S Abst#POS319 #EULAR2023 @RheumNow https://t.co/C2ADAkkSM2